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1. Abstract
Drug resistance remains a major problem for the treatment of HIV. Resistance can occur
due to mutations that were present before treatment starts or due to mutations that occur
during treatment. The relative importance of these two sources is unknown. We study three
different situations in which HIV drug resistance may evolve: starting triple-drug therapy,
treatment with a single dose of nevirapine and interruption of treatment. For each of these
three cases good data are available from literature, which allows us to estimate the probability
that resistance evolves from standing genetic variation. Depending on the treatment we find
probabilities of the evolution of drug resistance due to standing genetic variation between
0 and 39%. For patients who start triple-drug combination therapy, we find that drug
resistance evolves from standing genetic variation in approximately 6% of the patients. We
use a population-dynamic and population-genetic model to understand the observations and
to estimate important evolutionary parameters. We find that both, the effective population
size of the virus before treatment, and the fitness of the resistant mutant during treatment,
are key-parameters that determine the probability that resistance evolves from standing
genetic variation. Importantly, clinical data indicate that both of these parameters can be
manipulated by the kind of treatment that is used.
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2. Introduction
For most HIV patients, treatment with modern antiretroviral therapy leads to a rapid
decline of viral load (VL) of several orders of magnitude. However, when the virus acquires
resistance to one or more drugs, treatment can fail. It is still an open question whether the
mutations responsible for resistance originate usually from standing genetic variation (also
referred to as pre-existing mutations or minority variants), or from new mutations which
occur during therapy. In fact, there is no biological system for which the relative role of pre-
existing and new mutations is well known (Barret 2008). The case of HIV drug resistance
may serve as a good case-study for evolutionary biologists. In addition, understanding the
role of pre-existing drug resistance mutations may help guide the design of better treatment
strategies to reduce the risk that resistance evolves in patients.
In this paper we will look at the establishment of drug resistance mutations in three
different situations: (1) when triple-drug therapy (ART) is started for the first time, (2)
when pregnant women are treated with a single dose of nevirapine to prevent infection of
the baby during birth and (3) when standard therapy is interrupted and restarted. We will
argue that standing genetic variation plays a crucial role in each of these cases. We find that
the probability that resistance mutations become established in each of these cases can be
understood by using a simple population genetic model.
For readers who are not familiar with HIV, it is important to know that the genotype-
phenotype map for drug resistance in HIV is very well known. Lists of the important re-
sistance mutations for each drug are published (e.g. in the International AIDS SocietyUSA
drug resistance mutations list, Johnson 2010), so that doctors can compare the genotype of
the virus of a patient before treatment with this list to decide which drugs to prescribe. The
aim of treatment is to achieve viral suppression. If treatment fails despite adherence to the
regimen, a second genotypic test will be performed to see whether the virus has acquired
new resistance mutations. Since the second half of the 1990s, treatment is usually with a
combination of three drugs, which are chosen such that mutations which confer resistance
against one of the drugs do not confer cross-resistance against the other two drugs. Soon it
became clear that triple-drug therapy was an enormous success and saved the lives of many
HIV patients (Mocroft 1998). One reason why therapy with three drugs works better than
treatment with one or two drugs is that the rate at which resistance evolves is slower when
patients are treated with three drugs (Deeks 1998). It is commonly thought that resistance
does not evolve in patients on triple-drug therapy because it would require a viral particle
to acquire three mutations at the same time. However, in patients who are treated with
triple-drug therapy, it is often observed that resistance against one of the drugs evolves, at
least initially. Data from several cohort studies in different parts of the world, such as from
Canada (Harrigan et al 2005) and the UK (UK CHIC cohort study, Cozzi-Lepri 2005) clearly
show that in most patients who fail therapy due to resistance, the virus is resistant against
one of the drugs and almost never against all three. The UK study, for example, reports that
out of 4306 patients who started therapy between 1996 and 2003, after two years of therapy,
13% have drug resistance, but less than half of these patients (6%) have resistance against
more than one class of drugs and a only small number of patients (1%) have resistance against
3 classes of drugs, even though all patients of this cohort were treated with three classes of
drugs. These data show that treatment can fail due to resistance against one of the drugs
in a regimen. The viruses that have acquired resistance against two or three classes of drugs
may have acquired several drug resistance mutations at the same time or they may have
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acquired resistance against one drug first and subsequently acquired resistance against the
other classes. In order to distinguish between these two possibilities, a very dense sampling of
a patient’s viral population would be needed. For now, we will assume that in most patients
the accumulation of resistance mutations is a gradual process.
For many common drugs, especially reverse transcriptase inhibitors, a single mutation
can confer resistance against the drug and only a small number of mutations is respon-
sible for resistance in most patients. For example, resistance against the drug nevirapine
is almost always due to one of two amino acid changes, namely K103N or Y181C in the
reverse-transcriptase gene (Paredes et al 2010). Because of the importance of a small num-
ber of mutations, several studies have investigated whether these mutations are present in
untreated patients due to transmitted drug resistance or due to spontaneous mutation. Re-
cent studies have used allele-specific PCR and related methods to determine the frequency of
several important mutations in untreated patients. Low-frequency drug resistance mutations
(DRMs), likely due to spontaneous mutation (and not transmitted from other patients) were
detected in up to 40% of patients (see Gianella and Richman 2010 for an overview). The
detection of drug resistance mutations in untreated patients, together with the knowledge
that a single mutation can confer resistance against a drug and allow viral escape, suggest
that pre-existing resistance mutations (or standing genetic variation in the population genetic
jargon) may play an important role in the evolution of drug resistance in HIV.
Throughout the paper, we will assume that a single mutation can allow viral escape and we
focus on the probability that such a first drug resistance mutation becomes established (i.e.,
it reaches such a frequency that it can be expected to become the majority variant unless
treatment is stopped or changed quickly). What happens after a first mutation has become
established, or how fast such an established mutation wanes in the absence of treatment are
important questions, but they fall outside the scope of this study. In this paper, ‘triple-drug
therapy” refers to treatment with two drugs of the class NRTI plus either an NNRTI or an
unboosted PI (for a list of abbreviations in the paper, see Table 2). The results are likely to
be different for other drug combinations.
Starting therapy. When a patient starts therapy for the first time, one would expect that
there should be a substantial probability that drug resistance evolves due to pre-existing
DRMs. Indeed, recent studies have shown that the presence of drug resistance mutations
at low frequency (<1%) increases the risk that treatment fails (e.g., Johnson 2008, Geretti
2009, Paredes 2010, see Li et al 2011 for a review). However, the situation is not as simple
as one may hope: even if no pre-existing DRMs can be detected, resistance mutations may
become established quickly, and even if DRMs are detected, treatment is still successful in
the majority of patients. We will attempt to understand those observations using population
genetic theory. Other authors have looked at the question of pre-existing DRMs previously
(e.g., Bonhoeffer and Nowak 1998, Ribeiro and Bonhoeffer 2000), however, it is worth re-
considering the topic. First of all, we now have a wealth of data available for pre-existing
DRMs and the establishment of drug resistance mutations in HIV patients, and secondly, we
now have a better theoretical framework to consider the role of standing genetic variation for
adaptation (Hermisson and Pennings, 2005).
Prevention of mother to child transmission (PMTCT). Pregnant women in low resource
settings are often treated with a single dose of the non-nucleoside reverse transcriptase in-
hibitor neverapine when labor starts. Single dose nevirapine (sdNVP) is the cheapest and
simplest way to reduce the probability of mother-to-child-transmission, but it is shown to
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lead to the establishment of drug resistance mutations in the mothers and the babies. In a
meta-analysis, Arrive et al (2007) found that, in 7 different studies, on average 44% of the
patients treated with sdNVP had detectable NVP resistance mutation several weeks after the
treatment. The presence of such mutations makes future treatment of these women harder
(Lockman et al 2007). To avoid the establishment of resistance mutations, several alterna-
tive strategies are used in combination with sdNVP. We will use the same population genetic
framework as in the other two cases to try to understand why sdNVP leads to establishment
of resistance mutations in so many patients, and how this can be avoided. In the current
study we will only focus on the probability that NVP resistance mutations become estab-
lished during treatment for PMTCT. The issue of how these mutations wane and possibly
resurface when treatment is started again is important and interesting but falls outside the
scope of the current paper.
Treatment interruptions. It was long suspected that treatment interruptions lead to drug
resistance. Indeed, cohort studies show that treatment interruptions due to non-adherence
are associated with faster accumulation of drug resistance mutations (Tam et al 2008, Gard-
ner 2010, Lima 2010). Clear evidence that treatment interruptions of at least a couple of
weeks lead to the establishment of resistance mutations comes from clinical trials (e.g., Yerly
2003, Danel 2006, 2009) which were done in a time when it was believed that treatment
interruptions may be beneficial for patients. In 2006 the SMART trial was stopped because
treatment interruptions were shown to have a negative effect on patients’ health (El-Sadr
2008). However, treatment interruptions still occur, for example, when a patient is forget-
ful or is unable to purchase drugs due to financial or logistic barriers. It is important to
understand how treatment interruptions lead to resistance and whether this effect can be
avoided.
The main idea that currently governs the thinking about treatment interruptions and re-
sistance is that insufficient drug-levels allow for replication and, at the same time, select for
resistance (e.g., Taylor 2007, Fox 2008, Gardner 2010). This effect is aggravated when drugs
that are part of combination therapy have very different half-lifes, so that interrupting com-
bination therapy can result in effective monotherapy. It is generally believed that this “tail
of monotherapy” is the main reason why treatment interruptions lead to drug resistance.
However, several observations are not compatible with the “tail” hypothesis. For example,
Fox et al (2008) found no significant difference in the number of resistance mutations after si-
multaneous, “staggered” or “switched” treatment interruptions in patients from the SMART
trial (a “staggered” stop means that the long half-life drug is interrupted several days before
the other drugs and a “switched” stop means that before interrupting, patients switch to a
regimen with only short half-life drugs). In addition, the “tail” hypothesis fails to explain
why treatment interruptions increase the risk of resistance in patients on protease inhibitor-
based (PI) regimens which do not have long half-lifes (Dybul 2003, Yerly 2003, Arnedo-Valero
2005, Henry 2006, Ruiz 2007, Darwich 2008). Another explanation is needed to understand
the observed patterns.
When treatment is interrupted, the viral load rapidly increases until it has reached its
original level after approximately four weeks (Davey et al 1999). Basic population genetics
tells us that such population growth also leads to an increase in the probability that DRMs
are present. When treatment is started again, selection may work on such pre-existing
mutations, which provides a simple explanation for how treatment interruptions lead to the
establishment of resistance mutations.
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In this paper we will attempt to explain the observed patterns by considering selection
on pre-existing variation and selection on new mutations. Throughout the paper, we use
a mathematical model for adaptation from standing genetic variation which we developed
previously (Hermisson and Pennings, 2005) and forward-in-time, individual-based computer
simulations. The model captures mutation, drift and selection, including changing selection
pressures (due to stopping and starting of therapy) which lead to changes in population size.
Because we only focus on the establishment of the first drug resistance mutation, we can
ignore epistatic interactions between different drug-resistance mutations and recombination.
In each of the three cases of interest, we use published data on the percentage of patients with
established drug resistance mutations to estimate important parameter values (for starting
ART or sdNVP) and to predict outcomes (for treatment interruptions).
3. Model, assumptions and fixation probability of a drug resistance
mutation
The model we use in this paper describes the population dynamics and population genetics
of a panmictic viral population in a single patient. Details of the model can be found in the
supplementary material. We assume that as long as the patient is not on anti-retroviral
therapy, the viral population will be stable at population size Nu (u for untreated). Drugs
reduce the fitness of the wildtype virus to below 1 so that the population will shrink. We
assume that there is a large reservoir of latently infected cells of which a fixed number (I)
become activated per generation, so that the virus can not die out. Drug resistant virus
can be created by mutation and is assumed to be resistant against one of the drugs in the
treatment regimen. If the patient is not taking drugs, the drug resistant virus is less fit than
the wildtype by a factor Crel (relative cost of the resistant virus), but if the patient is taking
drugs, the resistant virus has a fitness that is higher than 1 (FmART > 1), whereas the
wildtype has a fitness lower than 1 (FwtART < 1). In reality, there may also be resistance
mutations that confer resistance against one of the drugs, but that do not lead to a fitness
higher than 1. Such mutations will quickly die out and can safely be ignored in the model.
Throughout the paper we focus on the the processes that allow a first major drug resistance
mutation to become established in the patient. Patients are assumed to be ART-naive and
have no transmitted drug resistance.
Evolutionary biologists have long known that most mutations will be lost by genetic drift
even if they confer a fitness benefit (Haldane 1927). This is also true for drug resistance
mutations (DRMs) in patients on anti-retroviral therapy, although it is all too often ignored
in drug resistance studies. The clinical relevance of this old result has recently become very
clear. It was found in several studies that even though low frequency DRMs increase the
risk of treatment failure and establishment of drug resistance, the majority of patients with
detected low frequency DRMs will respond well to treatment (Paredes et al 2010). This
result shows that DRMs can die out, even if they have reached frequencies high enough to
be detected. The reason is probably that most viral particles will not infect any new cells
and produce no new viral particles, even if, on average, they produce more than 1. Because
of stochastic effects, not every particle will have the same number of offspring and if some
have many, then others must have 0.
The probability that a DRM becomes established in the patient depends on the number
of copies that are present, the average number of offspring of the drug resistant particles
and the variance in offspring number. Traditionally, fixation or establishment probabilities
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are calculated using the relative fitness difference between the mutant and the wildtype,
but in the case of HIV it is more useful to use the fitness of the mutant virus to calculate
its establishment probability. The reason is that anti-retroviral therapy works so well that
wildtype fitness may be very low (much lower than 1). In such case fitness of the mutant
may not be related to the fitness of the wildtype and because the wildtype cannot grow, the
two types do not compete for resources. In other words, the mutant can occupy a niche that
is not occupied by the wildtype. In those cases the establishment probability of the mutant
will be approximately Pest ≈ 2∗(Fm−1)σ where σ is the variance in offspring number. In the
simulations and throughout this paper, we use the variance effective population size, in which
case one can assume that σ = 1, so that
(1) Pest ≈ 2 (Fm− 1)
It is important to realize that if the establishment probability of a DRM depends on its
absolute fitness, anything that reduces its fitness will reduce the establishment probability.
For example, if a drug that is added to a regime reduces fitness of both wildtype and resis-
tant virus, then it will reduce the probability that a pre-existing resistant mutant becomes
established. This is true even if the effect of the added drug on wildtype and resistant virus
is exactly the same. Similarly, if the immune system works well, this may also reduce the
probability of establishment.
In most population genetics models, the focus is on the fixation probability, rather than
the establishment probability of a mutation. And in many models, if a mutation becomes
established, it will go to fixation. However, if selection pressures change, establishment does
not necessarily lead to fixation. This is especially clear when we will later consider the effect
of a single-dose of nevirapine. A few weeks after a single dose of nevirapine, nevirapine
resistance mutations can be detected in a large proportion of patients, but these mutations
may never take over the whole viral population, because the treatment duration is very short
and wildtype virus will quickly become a majority again (see for example, Lockman 2007).
In fact, the standard results on fixation probability (Haldane 1927) are really results on
establishment probabilities, so we can use them without problems.
Psgv vs. Pnew. For drug resistance to evolve, the viral population needs viral particles
that carry drug resistance mutations. Such particles may already be present before treatment
is started. To denote this possibility we use Psgv or the probability that drug resistance
establishes from the standing genetic variation. If the mutation is not already present,
or if was present but was subsequently lost, then the viral population has to wait for a
new mutation to occur and become established. We denote this possibility as Pnew, or the
probability that resistance evolves due to new mutations. In the latter case, we have to
indicate a time window, such as per year or per generation.
The goal of this study is to understand and, albeit roughly, quantify Pnew and Psgv for HIV
drug resistance in patients on triple-drug regimes (consisting of an NNRTI or an unboosted
PI plus two NRTI’s) and in patients who are treated with single dose nevirapine.
4. Starting standard therapy
When a patient starts anti-retroviral therapy for the first time, the viral population in
that patient will move from an equilibrium without drugs to an equilibrium with drugs. At
the pre-treatment equilibrium, the viral population size will at its equilibrium level (Nu),
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and resistance mutations are expected to be at mutation-selection-drift equilibrium, where
most mutations will be present at very low frequencies (see, e.g., Paredes 2010). Note that
mutation-selection-drift equilibrium is reached quickly for mutations that are very costly to
the virus. So even though it may take years for neutral diversity to reach an equilibrium level
in an HIV patient (Kouyos et al 2011), important drug resistance mutations which are 5 or
10% less fit than the wildtype are expected to reach their (dynamic) equilibrium in weeks or
months.
Standard population genetic theory predicts that the average frequency of a resistance
mutation is equal to the mutation rate (µ, per viral particle and per replication) divided
by the relative cost (Crel) of the resistance mutation, though drift causes actual frequencies
to vary greatly between different time points and between patients (see also Gadhamsetty
et al 2010). Even though the average frequency is independent of the population size, in
larger populations, it is more likely that DRMs are present and the absolute number of drug
resistant particles will, naturally, be higher. When treatment starts, resistance mutations
will confer a fitness benefit to the virus and they can (but are not guaranteed to) increase in
frequency and become established. The probability that this happens depends on the number
of resistant particles in the population and on the establishment probability of a mutation
that is present in a single particle. In Hermisson and Pennings (2005) we derived formulas to
calculate the probability that adaptation to a new environment happens from the standing
genetic variation (Psgv). We will use the approximate equation 8 in Hermisson and Pennings
(2005):
(2) Psgv ≈ 1− (1 + 0.5 Pest
Crel
)−2µNu
It is also possible to use the the number of resistant particles in a patient (B) and the
fitness of these copies (in the environment with drugs) to calculate the probability that a
resistance mutation becomes established:
(3) Psgv = 1− (1− Pest)B
where we use the probability that all copies of the resistance mutation die out to calculate
the probability that at least one survives. The probability that resistance mutations become
established increases with the number of copies of resistant virus and the probability that
any one of these survives.
Evolution of resistance during therapy. If resistance did not evolve from standing
genetic variation, it may evolve due to new mutations. The probability that this happens in
a given year will depend on the number of generations (G) in a year, the mutation rate (µ),
the effective population size during antiretroviral treatment (NART ) and the establishment
probability of a mutation (Pest). In principle, the establishment probability during therapy
may not be the same as in the very beginning of therapy, for example because the number of
available cells which a particle can infect could be different. However, throughout this paper
we will assume that Pest depends only on the kind of therapy and not on how long a patient
has been treated. Using a poisson approximation, we find that the pre year probability that
resistance evolves is
(4) Pnew = 1− exp (−G NART µ Pest)
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It is debated whether during therapy, there is ongoing replication or whether a reservoir
of latently infected cells is entirely responsible to residual viremia. If the reservoir reflects
the composition of the viral population before treatment, then the expected frequency of the
resistance mutation in the reservoir would be µ
Crel
. If the number of latently infected cells
that become activated every generation is NLAT , then the expected number of activated cells
with resistant virus would be NLAT µ
Crel
. The per year probability that resistance evolves due to
activated cells from the reservoir would be
(5) Pnew = 1− exp (−G NLAT µ Pest
Crel
)
It is also possible that there is ongoing replication, but that the reservoir also plays a role
at the same time, so that the reality will be reflected best by a combination of equations 4
and 5.
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Figure 1. The probability that resistance is detected for the first time in the first,
second or third year of treatment, given that it was not detected until then. The bars
are the estimates from the Margot et al (2006) dataset. The red dashed area reflects
the inferred probability that resistance mutations from standing genetic variation
become established. The grey squares are values calculated using equations 2 and 4.
The red circles are estimated from 1000 simulations. Parameters as in table 1.
Comparison with data and parameter estimation Published data show that the rate
of evolution of drug resistance is roughly constant over long times (see for example the study
by Cozzi-Lepri et al (2010), in which patients were followed for up to eight years). This fits
with expectations if NART and Pest remain constant so that Pnew stays constant. However,
several studies show that the probability that resistance mutations become established is
higher in the first year of therapy, as compared to later years. This can be seen, for example,
in a study on a large cohort in British Columbia, especially when one considers the most
adherent group of patients (figure 2 in Harrigan et al 2005, see also Tam et al 2008). A similar
effect is seen in Li et al (2011) when one considers the patients with pre-existing DRMs. This
effect, that resistance is more likely to evolve in the first year of therapy as compared to later
years, can be easily explained by standing genetic variation.
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Possible combinations of population size and fitness
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Figure 2. 2a. Continuous line: combinations of population size before treatment
(Nu) and fitness of mutant virus during therapy (FmART that lead to the observed
probability that resistance mutations from standing genetic variation become estab-
lished (Psgv = 0.058). Dashed line: combinations of population size during treatment
(NART ) and fitness of mutant virus during therapy (FmART that lead to the observed
probability that resistance mutations from standing genetic variation become estab-
lished (Psgv = 0.058). Open dot: Nu = 2000 and FmART = 1.017, closed dot:
NART = 108, FmART = 1.017. 2b. Probability that a patient has any pre-existing
DRMs before the start of therapy for different population sizes, and µ = 5 ∗ 10−5.
Open dot: Nu = 2000
Under the assumption that Pnew is indeed constant, we can use published data to estimate
both Pnew and Psgv. Margot et al (2006) reported the number of patients in which resistance
was detected in the first, second and third year after treatment initiation in a cohort that was
treated with NNRTI-based ART. The reported data show that the probability that resistance
was detected in the first year was 9.5%, whereas in the second and third year it was only
3.7% (see supplementary material for details on how this was estimated). The difference of
5.8% is likely due to standing genetic variation at the start of therapy.
We will use the estimates for Pnew (0.037 per year) and Psgv (0.058) from Margot et
al (2006), in combination with other, published, estimates to get a rough estimate of the
important evolutionary parameters. First of all, we will assume that the mutation rate from
one nucleotide to a specific other nucleotide is 10−5 (Mansky and Temin 1995), so that if
there are five main resistance mutations for a given drug combination, the total mutation rate
is approximately 5 10−5. For the remainder of the paper, we will only use this total mutation
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rate. If the mutation rate would be higher (lower) than our assumption, the estimated
population sizes would be lower (higher) than our estimates.
We know that the important drug resistance mutations are at least somewhat costly for
the virus. Their cost, Crel, has been estimated for several drug resistance mutations, both in
vivo and in vitro (for an overview on resistance mutations in the reverse transcriptase gene
see Martinez-Picado 2008). For example, Paredes et al (2009) find that the relative cost of
resistance mutation M184V is approximately 0.04− 0.08. Wang et al (2011) estimate a cost
of 0.01 − 0.04 for K103N, which is the most common NNRTI resistance mutation. Other
studies were not able to detect any cost of K103N, but given its low frequency in untreated
patients (Paredes et al 2010), it seems likely that it is associated with a significant cost. In
this paper we will use an average cost of 0.05 for all mutations.
Given the cost, the mutation rate, Psgv and Pnew, and using the assumption that there are
200 HIV generations in a year (Fu 2001), we can find the combinations of Nu, NART and
FmART that are compatible with the data (shown in figure 2). Estimates for the effective
population size in untreated patients range from 103 (Leigh-Brown 1997) to 105 (Rouzine and
Coffin 1999). We know that a large proportion of untreated patients carries low frequency
drug resistance mutations, but not all patients, which gives us some additional information
about the population size in an untreated patient (see figure 2b). If we choose a value of Nu
of 2 103, then we find that about half of the patients should carry pre-existing DRMs. This is
somewhat higher than what is usually detected, but that can be due in part to the limits of
detection of current tests (Gianella and Richman 2010). An overview of parameter estimates
which we used in the simulations and for analytical predictions can be found in table 1.
Given our choice of Nu, we find that FmART must be approximately 1.017, leading to
Pest ≈ 0.034. Under the assumption Pest stays the same during treatment, the Margot
et al data are compatible with a 18-fold reduction of population size due to therapy, to a
population size of NART ≈ 108. Note however, that the estimate of a 18-fold reduction
depends heavily on the assumption that Crel = 0.05. For example, if we had assumed a 10%
cost, the estimated reduction would have been 37-fold, and for a 1% cost, the reduction would
have been only 4-fold. The reason is that if we assume that costs are high, then we must also
assume that the mutant fitness (FmART ) is relatively high, in order to find Psgv = 0.06, and
if FmART is high, NART must be low, to explain Pnew = 0.037.
If the evolution of resistance during therapy is not due to ongoing replication, but due
to continuous activation of latent cells, then, under the assumption that Crel = 0.05, the
number of cells (NLAT ) must be approximately 5 per generation. This means a reduction of
population size of almost 400-fold. However, it is not so clear whether in this case the word
“population size” should still be used, because the number 5 is not an estimate of the size of
the reservoir, but an estimate of the size of the part of the reservoir that is reactivated every
generation.
The result that the frequency of resistance mutations in the reservoir depends on their
fitness cost ( µ
Crel
), whereas the cost does not play a role for new mutations due to ongoing
replication, could be harnessed to estimate the relative importance of the reservoir. If the
reservoir is the most important source of resistance mutations during therapy, then the same
set of mutations should be found in patients whose virus acquires resistance quickly after the
start of therapy and in those who acquire mutations during therapy. However, if ongoing
replication is the source of resistance mutations during therapy, then mutations with a high
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cost in the absence of drugs should occur relatively more often during therapy than quickly
after therapy is started.
The data and the results from simulations and predictions (using equations 2 and 4) are
shown in figure 1. The percentage of patients with resistance after one year is lower in the
simulations than in the analytical predictions, because it takes time for a mutation to increase
in frequency and be detected. We assume that it is detected as soon as it is more frequent
than the wildtype, the result is that in the simulations (and probably in reality) Pnew is lower
in the first year than in the other two years.
Table 1. Parameter values for analytical predictions and computer simulations.
Parameter Value Explanation
Values roughly based on lit-
erature
µ 5*10-5 Mutation rate to resistant genotype
Nu 2000 Effective population size in untreated patient
Crel 0.05 Relative cost of mutant in absence of therapy
FwtART = FwtNV P 0.5 Absolute fitness of wildtype during therapy
G 200 Number of HIV generations per year
Values estimated based on
data
NART 108 Effective population size in patient on ART
NLAT 5 Number of activated latent cells in patient on ART
NZDV 1000 Effective population size in patient on ZDV monotherapy
Fwtu 1.62 Absolute fitness of wildtype in absence of therapy (determines growth rate
during treatment interruption)
Fmu 1.54 Absolute fitness of resistant mutant in absence of therapy
FmART 1.017 Absolute fitness of resistant mutant during ART
FmNV P 1.54 Absolute fitness of resistant mutant during NVP therapy
FmNV P/PP 1.025 Absolute fitness of resistant mutant during NVP/PP therapy
I 135 Number of particles from latent cells that enter the population per generation
Table 2. Abbreviations.
Abbreviation Explanation
VL Viral load, the number of viral particles per ml blood
ART Antiretroviral therapy, here used to mean treatment with two NRTIs and an NNRTI or an “un-
boosted” PI
PMTCT Prevention of mother to child transmission
DRM drug resistance mutation
NRTI Drug of class nucleoside reverse transcriptase inhibitor
NNRTI Drug of class non-nucleoside reverse transcriptase inhibitor
PI Drug of class protease inhibitor, PIs can be used “unboosted” or “boosted” with an additional drug.
NVP Nevirapine, an NNRTI
sdNVP Single dose nevirapine
ZDV Zidovudine, also known as AZT, an NRTI
3TC, DDI, FTC, TDF Drugs of NRTI class
5. Single-dose nevirapine for prevention of mother-to-child-transmission
A single dose of nevirapine (sdNVP) just before labor starts reduces the risk that a mother
transmits HIV to her baby at birth, but leads to high levels of resistance in many women.
Because of the long half life of nevirapine, even a single dose lasts at least a few days.
However, this is a very short amount of time (only a few HIV generations) so that probably
most or all detected NVP resistance mutations are due to standing genetic variation.
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Because it is known that sdNVP can lead to the establishment of resistance mutations,
and also to further reduce the risk that the baby becomes infected with HIV, several dif-
ferent treatment strategies are being used. In this study, we focus only on those strategies
that include a single dose of nevirapine (and exclude, for example, pregnancy limited triple-
drug therapy). Basically, sdNVP can be combined with either a short course of zidovudine
monotherapy during the third trimester of pregnancy (ZDV/sdNVP), or it can be combined
with additional drugs during and after labor up to one month postpartum (sdNVP/PP). It
can also be used alone (sdNVP) or combined with both (ZDV/sdNVP/PP), resulting in four
possible strategies.
Under the assumption that all resistance is due to standing genetic variation, it is straight-
forward to predict, at least qualitatively, the effect of the four treatment options. Single dose
nevirapine plus two additional drugs (sdNVP/PP) is a three drug regimen, and similar to
standard antiretroviral therapy (ART), except that it only lasts a few days or weeks. We
therefore expect similar levels of drug resistance due to standing genetic variation. If only
NVP resistance is considered (and not resistance to the other two drugs), we expect to find
somewhat lower levels than in the normal case, although the difference may not be large be-
cause resistance against NVP is more common than resistance to most other drugs. Treating
with only sdNVP is different from starting ART, in that there is only one drug. The result
is that the fitness of both wildtype and resistant virus will not be reduced as much as in the
normal case. Specifically, NVP resistant virus will have a relatively high fitness during NVP
monotherapy. This high fitness (FmNV P ) leads to a high establishment probability (Pest) for
available resistance mutations. In fact, the establishment probability may be so high that in
virtually all patients that carry some NVP resistance before treatment, the resistant virus
will increase in frequency during NVP treatment.
An interesting treatment option is to start with a few weeks of ZDV monotherapy before
treating with a single dose of nevirapine. The ZDV treatment will reduce the population
size of the virus, Nu, so that the probability that NVP resistance is available and the copy
number of such resistant mutants if they are available will be lower by the time the patient is
treated with NVP. ZDV monotherapy ultimately leads to ZDV resistance, but the risk that
resistance mutations become established during a short course is small. ZDV monotherapy
reduces the viral load approximately three-fold (BrunVezinet 1997). Finally, adding ZDV
treatment before labor and two additional drugs during and after labor (ZDV/sdNVP/PP)
will reduce both the availability of NVP resistant virus and the establishment probability of
such virus, which should lead to an even lower probability that NVP resistance mutations
from standing genetic variation become established.
Comparison with data for single dose nevirapine. We identified 23 published studies
that reported on NVP resistance 6 to 8 weeks after women were treated with sdNVP. Several
of the studies directly compared two different treatment options. We found at least three
studies for each of the four different treatment options. An overview of the studies can be
found in table 4 in the supplementary material. For each study we recorded which of the
four treatment options was used and in how many of the patients NVP resistance mutations
were detected using simple Sanger (population) sequencing (we excluded studies that only
recorded deep-sequencing or allele-specific PCR results, as there were too few of those to
allow us to compare the treatment options). For each of the four treatment options, we also
calculated the overall probability that resistance mutations were detected in a patient (simply
by summing the number of patients with resistance and summing the total number of patients
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Figure 3. The probability that resistance mutations are detected 6 to 8 weeks
after treatment with single dose nevirapine. Black crosses are data from single
studies (the number of studies is indicated in brackets at the top of the graph),
black squares with estimated standard error are percentages for all studies combined
(the number of patients that were used to calculate this percentage is indicated
at the top of the graph). Red circles with standard error are results from 1000
simulations and the grey squares are analytical predictions. Parameter values as in
table 1. sdNVP stands for single dose nevirapine, ZDV stands for third trimester
zidovudine monotherapy, PP stands for the addition of two drugs during and after
labor (postpartum).
in the studies). We found that sdNVP leads to detectable resistance mutations in 39% of
952 patients, ZDV/sdNVP leads to detectable resistance mutations in 22% of 888 patients,
adding two drugs during and after labor (sdNVP/PP) lead to detectable resistance mutations
in 7.8% of 372 patients and ZDV/sdNVP/PP lead to detectable resistance mutations in none
of 292 patients.
We now used these data, in combination with our previous parameter estimates, to estimate
the fitness of a NVP resistant mutant during NVP therapy (FmNV P ) and the reduction of
the population size due to ZDV treatment (NZDV ). We find that FmNV P ≈ 1.54 and that
ZDV reduces the effective population size approximately two-fold (table 1 and figure 3).
The results show that a reduction in population size by ZDV monotherapy does reduce the
probability that NVP resistance mutations become established, but adding two drugs to
sdNVP helps much more. We also estimate of the fitness of the mutant during therapy
with nevirapine and two additional drugs and find a slightly higher value than our previous
estimate (1.025 vs 1.017), because the estimated probability that resistance mutations from
standing genetic variation become established is slightly higher (0.078 vs 0.058 with standard
therapy), though these differences are not statistically significant.
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Figure 4. The probability of the establishment of drug resistance mutations from
standing genetic variation depending on the effective population size and the fitness
of the resistant mutant during therapy. Grey scales indicate the probability of the
evolution of drug resistance due to standing genetic variation. Dots indicate esti-
mated parameter combinations for treatment with just sdNVP, with ZDV monother-
apy followed by sdNVP (ZDV/sdNVP), by sdNVP followed by two additional drugs
postpartum (sdNVP/PP) and with ZDV monotherapy followed by sdNVP and two
additional drugs postpartum ZDV/sdNVP/PP.
6. Interruption of therapy
During a treatment interruption, drugs are first removed from the body, which can take
from a couple of hours to a several days or even weeks (Van Heeswijk 2000, 2001, Pirillo 2010).
With some delay, depending on the half-life of the drugs, the viral population begins to grow,
which is observed as an increase of viral load. Published data show that after treatment is
stopped, viral load quickly increases in almost all patients (e.g., Harrigan 1999). Davey et
al (1999) show that average viral load plateaus four weeks after treatment is interrupted.
Garcia et al (2001) and Trkola et al (2005) both report that a plateau is reached between
four and eight weeks after treatment interruptions. An interruption is ended when treatment
is started again and viral load goes down, hopefully to undetectable levels. Figure 1 shows a
cartoon of the pharmacodynamics and population dynamics of a treatment interruption.
Restarting therapy. If the length of a treatment interruption is so long that the pop-
ulation size is back to pretreatment level and mutation-selection-drift equilibrium is again
reached, the probability that resistance mutations become established when therapy is started
again will equal the probability that resistance mutations become established the first time a
patient starts treatment, Psgv from equation 2. But if a treatment interruption is shorter than
that, it is hard to calculate the exact probability that resistance will evolve upon re-initiation
of therapy because neither population-dynamic, nor population-genetic equilibrium will have
been reached. The absence of the population-genetic equilibrium is most problematic if re-
sistance mutations are not very costly to the virus. However, for a costly mutation it takes
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Figure 5. Drug level (dashed line) and viral population size (solid line) during and
after a treatment interruption. Red bars indicate when drugs are taken.
only on the order of 1/Crel generations to reach mutation-selection-drift equilibrium. The
absence of population-dynamic equilibrium is less problematic, because it is relatively easy
to predict the population size of the virus or to measure viral load. In the simulations, we
allow the population to grow exponentially until it reaches the baseline level. The resulting
population size can be plugged into equation 2 to get an estimate of the probability that
resistance mutations become established due to a treatment interruption.
Comparison with data for treatment interruptions. Using the parameter values
from the last two sections, we can predict the risk that resistance mutations become estab-
lished due to a treatment interruption of a certain length. We use the estimated fitness of
the mutant virus during NVP therapy, and assume that the fitness of the mutant in absence
of drugs is the same. With that value, we can calculate the fitness of the wildtype in the
absence of drugs, because of the assumption that the cost of the resistance mutation is 5%.
The wildtype fitness will determine how fast the virus grows in the simulations after treat-
ment is interrupted, and therefore how long it takes before the population size is back at the
pretreatment level. Specifically, we use Fwt = 1.62. In the simulations, the population size
plateaus after just 14 days, but Psgv reaches its expected value only after 60 days (figure 6).
We collected information from structured treatment interruption trials to test the predic-
tions. The probability that resistance mutations become established due to a single treatment
interruption was estimated for seven clinical trials with different lengths of treatment inter-
ruptions (Ananworanich, 2003, Danel, 2009, Hoen, 2005, Palmisano, 2007, Reynolds, 2009
and 2010, Yerly 2003). An overview of the trials can be found in table (supplementary ma-
terial). We first calculated the risk under the assumption that all observed resistance was
due to treatment interruptions and then subtracted the estimated probability that resistance
mutations become established during therapy. The corrected values are shown in figure 6.
The data show that longer treatment interruptions indeed lead to a higher risk of resistance.
The risk plateaus around 37 days, which is consistent with the time it takes for viral load
to reach its equilibrium level (although the simulations suggest that the risk should plateau
later than the population size). The highest risk was found to be approximately 6% per
interruption, just like the risk of starting therapy for the first time.
7. Discussion
One aim of our study was to understand and quantify the importance of standing genetic
variation for the evolution of drug resistance in HIV. We find that the probability that at
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Parameters as in table 1.
least one resistance mutation becomes established due to standing genetic variation (Psgv)
depends on the kind of treatment chosen. Most clearly, it is much higher when treatment
is with sdNVP (which is monotherapy) than if treatment is with triple-drug combination
therapy. For standard combination therapy (ART), we use two different data sources to
estimate the probability that resistance mutations from standing genetic variation become
established. In the first part of this paper we used data on the number of patients in which
resistance was detected in the first year of treatment versus later years. In the third part of
this paper we used data from clinical trials on treatment interruptions. In both cases, we
found that the probability that resistance mutations from standing genetic variation became
established was approximately 6%.
The importance of new mutations as compared to pre-existing mutations could be esti-
mated from the Margot et al 2006 study. We estimated that the probability that a resistance
mutation becomes established during therapy (Pnew) is 3.7% per year, which means that pre-
existing mutations and new mutations are equally important after about one-and-a-half year
of treatment. Two of the interruption studies also provided estimates for Pnew, which were
slightly higher (4.3% and 4.8% per year) than the estimate from the Margot et al 2006 study
(see table 5). It is likely that some of the patients in these studies were not perfectly adherent
to treatment, so that our estimate of Pnew is inflated by patients who interrupted treatment.
This does not affect our estimates of Psgv. However, it means that the relative importance
of pre-existing mutations is highest in completely adherent patients (because new mutations
are relatively unimportant for them) and lower in non-adherent patients (see Paredes 2010,
but see Li 2011).
A stochastic model was used to understand the effect of standing genetic variation on
the evolution of drug resistance during HIV treatment. Four parameters are crucial to un-
derstand the role of standing genetic variation. Three of them determine the amount of
genetic variation that is available (effective population size, mutation rate and cost of the
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resistance mutations) and one determines how likely it is that the available mutations become
established (the absolute fitness of the resistant virus during treatment).
The cost and the mutation rate are parameters that are specific for each specific mutation.
Together, they determine the expected frequency of the mutant in an untreated patient.
For example, in untreated patients the frequency of K103N was found to be lower than the
frequency of Y181C (Paredes et al 2010), suggesting that µ/Crel is lower for K103N, possibly
because it reduces the fitness of the virus more. The costs for some of the most important
mutations (M184V, K103N) have been estimated and are between 1 and 10% (Martinez-
Picado 2008, Paredes 2009, Wang 2011). Throughout this paper we used a value of 5%.
The effective population size in an untreated patient (Nu) determines how much variation
there is in the frequency of resistant mutants between patients. If Nu > 1/µ, the frequency in
each patient will be very close to the expectation, µ/Crel, but if Nu < 1/µ, there will be a lot
of variation between patients, and in many patients no resistance mutations may be available
at all. Data suggest that in HIV the latter is the case (e.g., Paredes et al 2010), which means
that, contrary to common belief, not every single point mutation is created every generation
in an HIV patient. Nu also determines the number of resistant viral particles in a patient with
a given frequency of the mutant. With higher Nu, there will be a higher number of resistant
particles, and this makes it more likely that resistance mutations become established when
treatment is started (Li et al 2011).
We find that data are compatible with an 18-fold reduction of N due to ART and a two-fold
reduction of N due to ZDV monotherapy. The estimated reduction depends on the assumed
cost of mutations; if we assume that mutations are twice as costly, we would find a reduction
that is twice as severe. Still, the reductions we find are not nearly as severe as one may
have expected based on viral load reductions. During ART, VL may be reduced 1000-fold or
more (in the Margot (2006) from which we used the data study, patients had a viral load of,
on average, 8 104 before treatment, whereas after 48 weeks of treatment, about 80% of the
patients had a viral load of less than 50, Gallant 2004). This discrepancy may be due to two
effects: firstly, our estimate is an average for many patients and this average may be driven
up by patients in which the drugs do not work well, or who are not adherent to therapy so
that their VL does not go down as much as expected. Secondly, the relationship between
effective population size and viral load may not be linear, so that a thousand-fold reduction
in VL may translate in only a twenty-fold reduction in effective population size.
The fourth important parameter is the fitness of the mutant virus during treatment (Fm),
which determines the establishment probability (Pest). Fm will depend on both the drugs
that are used and on the specific mutation. For example, the resistance mutation K103N is
more likely to become established during sdNVP than during triple-drug therapy, because
additional drugs reduce Fm (FmART < FmNV P ). And during triple-drug therapy, K103N
is more likely to become established than Y181C (even though Y181C is present at higher
frequencies before treatment), likely because FmART is higher for K103N than for Y181C.
Starting of standard therapy. We assumed that the rate of evolution due to new
mutations is constant and that the establishment of a resistance mutation from standing
genetic variation leads to viral failure and is detected within one year of starting therapy.
Maybe the most convincing evidence for these assumptions comes from the Li et al (2011)
study, where their figure 2 shows that (1) patients without detected pre-existing DRMs show
a constant rate of evolution of resistance and (2) patients with detected pre-existing DRMs
show an increased rate compared to the patients without pre-existing DRMs, but only in the
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first year of treatment. We used these assumptions to estimate the probability that resistance
mutations from standing genetic variation become established. However, the estimated role
of standing genetic variation may be a slight underestimate, because establishment of new
mutations should need some time so that Pnew would normally be somewhat lower in the
first year of treatment. The observation that the effect of standing genetic variation only
lasts a year, means that fixation of a resistance mutation must take less than a year. This
limits possible values for NART and FmART to such values for which the fixation time is less
than 200 generations. For the current study, this means that, had we started with a larger
population size estimate, then we would have had to choose a higher value of FmART in
order to guarantee that pre-existing resistance mutations are detected (or lost) within a year
of therapy, which, in turn, would have led to a higher value of Crel to keep Psgv ≈ 6%.
If resistance indeed evolves due to standing genetic variation in 6% of patients on standard
ART, then there is clearly room for improvement. Note that those 6% of patients have
already lost their first treatment option shortly after having started treatment. They have
to switch to second-line treatment which is more expensive, usually more complicated (more
pills per day) and likely has more side effects. It is therefore worth exploring ways to avoid
the establishment of resistance mutations from standing genetic variation. Figure 4 suggests
two options to reduce Psgv, by reducing the population size or by reducing the fitness of
the resistant mutants. The first may be achieved by ZDV monotherapy, as shown in the
section on PMTCT, whereas the second may be achieved by adding additional drugs to the
treatment. Obviously, triple-drug combination treatment is already standard for most HIV
patients, but it may be worth considering specifically which treatment options would be
best to prevent the evolution of resistance from standing genetic variation. This may mean,
for example, to add a fourth drug to the therapy in the first couple of weeks of treatment.
Finally, when it becomes possible to detect low-frequency DRMs routinely in patients before
starting treatment, it may be possible to wait for a moment when their frequency is low to
start therapy.
Resistance due to sdNVP. Studying treatment with a single dose of nevirapine gives
us a unique opportunity to study the effect of standing genetic variation, because treatment
is so short (only a few HIV generations) that we can assume that most or all resistance
mutations that are detected are from standing genetic variation. Data show that the risk
that resistance mutations become established due to such treatment is very high (39%). We
find that this high probability can be explained entirely by selection on pre-existing drug
resistance mutations, because the fitness of NVP resistant virus is probably very high during
NVP monotherapy. We estimate that its fitness is approximately 1.5. Reducing this fitness,
by adding additional drugs or reducing the availability of the mutant by reducing population
size will both reduce the probability that resistance is established. A study from Zambia (Chi
et al 2007) showed that the additional drugs even help to reduce the establishment of NVP
resistance mutations if the drugs are given as a single dose (in stead of treatment for a couple
of days or weeks). We did not include this study in the overview, because there was only one
study that looked at this treatment option. However, the results are interesting: they find
that even a single dose of TDF/FTC reduces the probability that resistance mutations are
found 6 weeks after a sdNVP from 25 to 12 %.
The results on ZDV/sdNVP/PP treatment (i.e., treatment with ZDV during pregnancy
and NVP plus two other drugs during labor) are surprising in that NVP resistance mutations
were not detected in any of the women who received this treatment, even though the model
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would predict that mutations would be detected in 4% of the women. Most of the data on
this treatment option are from the Lallemant 2010 paper (222 women). In this study, the
authors do find some mutations that confer resistance to the NRTI’s in the study (in 2.3%
of the women). The same study also looked at women who were treated with ZDV/sdNVP
and also in these women the percentage with resistance mutations was very low (6.4%) and
much lower than the mean value for women who receive this treatment (22%). The reason
for the surprisingly low values of drug resistance in this study could be that the women in the
study had very low viral loads (median 2800), which is much lower than in most untreated
patients. This probably also means that they have a low effective population size. It therefore
seems unlikely that the extremely good results from the Lallemant study can be replicated
in other populations. However their results still show that using additional drugs to reduce
the population size and to reduce the fitness of the mutant may be a good strategy to reduce
the probability that resistance becomes established.
Treatment interruptions. Considering treatment interruptions, our model provides
several testable predictions. 1) resistance mutations are more likely to become established
after long treatment interruptions when viral loads are higher, 2) the risk that resistance
mutations become established due to a treatment interruption can not be larger than the
risk at the start of treatment, 3) treatment interruptions increase the risk of establishment
of resistance mutations even for drugs with short half-lifes.
Data from seven clinical trials show that indeed, longer interruptions increase the prob-
ability that resistance mutations become established (figure 6). Moreover, the estimated
probability appears to plateau after 37 days, which is similar to the time it takes for viral
load to reach its pretreatment level. This suggests that the risk of establishment of resis-
tance mutations is directly linked to the viral load when treatment is started again. However,
in our simulations, population size plateaued much earlier than the risk of resistance. Un-
fortunately, the resolution of both viral load measurements and of the data on treatment
interruptions are not good enough to determine whether in reality viral load indeed plateaus
before the risk or not. If both would plateau at the same time, it would suggest that the
resistance mutations are more costly than we had assumed. The second prediction was also
found to hold: the estimated risk that resistance mutations from standing genetic variation
become established at the start of treatment was found to be similar to the risk due to a
long treatment interruption (6% in both cases). The third prediction also holds, as data
show that interruptions increase the risk of establishment of resistance mutations even for
PI based treatment (Yerly 2003 and Hoen 2005), where the “tail of monotherapy” cannot
explain the observations.
A potential problem with the data is that not only the length of the interruptions, but
also the length of treatment periods between the interruptions differed between the seven
studies. The trials that were compared also differed in the drugs that were used (see table
5 in supplementary material), which makes direct comparison difficult. Despite all these
limitations, it becomes clear that longer interruptions carry a higher risk of evolution of
resistance than shorter interruptions.
If interruptions lead to the establishment of resistance mutations only due to the “tail of
monotherapy”, as is usually assumed in the HIV literature (Taylor 2007, Fox 2008, Gardner
2010), we would predict that: 4) treatment interruptions increase the risk that resistance
mutations become established only for drugs with long half-lifes, 5) the risk that resistance
mutations become established due to a treatment interruption is unrelated to the risk at
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the start of treatment and 6) the largest risk would be due to an interruption with a length
that is exactly the time it takes for the last drug to loose its effect on the wildtype virus.
All of these predictions do not hold. This is not to say that the “tail of monotherapy” is
not important at all. But it does show that on its own, the “tail of monotherapy” cannot
explain the risk that resistance mutations become established due to treatment interruptions.
When one considers possible intervention strategies, this may be good news. If treatment
interruptions are risky because of restarting rather than stopping therapy, this would give
doctors a possibility to reduce the risk that resistance mutations become established even
after a patient has already stopped taking his or her drugs.
The data on single dose nevirapine clearly show that monotherapy makes it likely that
resistance mutations become established, so intuitively, one would expect that monotherapy
should also be important also in patients who interrupt treatment, which is why the “tail of
monotherapy” hypothesis is so popular. However, in patients who are treated with sdNVP,
the resistance mutations are most likely already present, because it is the first treatment
they receive and the viral population will be large. On the other hand, if a fully suppressed
patient interrupts therapy, a few days of monotherapy may not have a large effect, because
the population size of the virus will be very small. Monotherapy in those patients would
still lead to a high establishment probability of resistance mutations, but if such mutations
are not present in the population, they cannot become established. The situation may be
different in patients who take treatment very irregularly, so that they are more likely to have
higher viral loads when treatment is stopped. This may explain why resistance to NNRTIs,
which are long half-life drugs, is likely to evolve in non-adherent patients (Tam et al 2008).
General remarks. We have used a population-dynamic and population-genetic model
to study several patterns of drug resistance in HIV. The model explains why resistance
mutations are likely to be established in the first year of standard treatment, in women who
are treated with a single dose of nevirapine and in patients who interrupt treatment. In all
three cases, standing genetic variation can explain the observations.
Our results illustrate that for adaptive evolution to happen, selection and the creation of
new variation need not happen at the same time, if selection can work on standing genetic
variation. In the case of antiretroviral treatment, this means that insufficient drug levels
(which allow for replication and selection at the same time) are not a necessary condition for
the evolution of drug resistance, although they would speed up such evolution. This result
about time-heterogeneous drug levels is similar to the result on heterogeneity in space by Ke-
pler and Perelson (1998), who showed that genetic variation may be created in compartments
where drugs cannot penetrate whereas selection happens in other compartments.
Note that our model provides a simple explanation for why resistance is less likely to
evolve when patients are treated with multiple drugs at the same time in stead of just one
drug. Additional drugs reduce the fitness of a mutant that is resistant against one drug, and
therefore the establishment probability of such a resistant mutant. In addition, additional
drugs reduce the population size of the virus and thereby the creation of new resistance
mutations. This means that there will be fewer resistance mutations with lower establishment
probabilities, together leading to a strong reduction in the probability that resistance evolves.
This model therefore explains why the evolution of drug resistance is slower with triple-drug
therapy, but not completely halted, as escape due to one mutation is still possible. In newer
therapies with boosted PIs, drug resistance has become very rare (Cozzi-Lepri 2010), which
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may be because boosted PIs are so strong that no single mutation can lift the virus’ fitness
above 1.
The model in this study, which includes the effect of population size on the probability
that resistance mutations become established may be relevant to other diseases than HIV.
For example, the evolution of resistance is a problem in chronic myeloid leukemia (CML)
which is a cancer of white blood cells. A recent study suggested that the probability that
drug resistance evolves in CML goes down with time because the population size of the cancer
goes down with time (Tomasetti, 2011, BCJ).
Resistance is also a problem in tuberculosis (TB), and in TB it is also known that treatment
interruptions increase the risk of evolution of resistance (Weis 1994). It should be investigated
whether this effect may also be due to an increased population size during the interruptions.
In general, stopping treatment may be risky when treatment has to be started again, which is
always the case for HIV and often for TB. Each time therapy is started, resistance mutations
from standing genetic variation may become established, and even if this risk is only a few
percent it adds up quickly when patients interrupt treatment regularly.
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10. Supplementary material
10.1. Model. The model describes population dynamics and population genetics of a pan-
mictic virus population in a single patient. Only virus in infected cells is considered and the
dynamics of free virus and uninfected cells are ignored. The total number of cells that can be
infected is limited to K, the carrying capacity. Because the life cycle of the virus is simplified
to just one step in which infected cells “give birth” to infected cells, all drugs have the same
effect: they reduce the number of cells that can be infected by the virus in an infected cell.
We will refer to the infected cells by the virus they are infected with.
When patients fail therapy, this is often due to virus that is resistant against just one
drug even if the patient was treated with three drugs (as described in the Introduction). We
therefore assume in our model that there are just two types of viruses: wildtype virus that
is susceptible to all drugs and resistant virus that is resistant against one of the drugs in the
regimen of the patient. We assume that prior to establishment of single drug-resistant virus
(hereafter: resistant virus), there is no virus present that is resistant against more than one
drug. We only focus on the probability that single drug-resistant virus becomes established.
The resistant type has a growth rate larger than 1 even in the presence of drugs, but in
the absence of drugs it is less fit than the wildtype. Initially the population consists of only
wildtype virus, resistant virus can be created by mutation. Absolute fitnesses are determined
for wildtype and resistant virus, in the absence of drugs (denoted by u for untreated) and
during treatment (either ART or NVP). These fitnesses are absolute fitnesses, which are
equivalent to the reproductive ratio, or the expected number of cells a viral particle would
infect in a completely susceptible population of host cells. Without drugs, wildtype virus is
fitter than resistant virus, so that the population will always be dominated by wildtype virus.
During treatment, resistant virus is fitter than wildtype, so that the population will ultimately
become dominated by resistant virus. However, if evolution is mutation-limited, it can take
a long time before the equilibrium with resistant virus is reached. One of the successes of
combination therapy is to make this waiting time much longer than with monotherapy.
The relative cost or selective disadvantage is defined as Crel = (Fwtu−Fmu)/(Fwtu), or,
in other words, how much less fit resistant virus is in the absence of drugs, relative to the
wildtype. As will be shown later, the fitness of the wildtype with drugs is not important in
the current model (although we do have to determine its value for the simulations).
If the average fitness of the viral population is larger than 1, the viral population grows
exponentially until it reaches the carrying capacity (K), at which point the population stops
growing and stays stable. If the average fitness of the population is below 1, the population
shrinks until it reaches I/(1− Fwt), where I is a fixed number of particles which is added to
the population each generation. This reflects the latently infected cells in an HIV infected
patient. These latently infected cells have very long half-lifes and function as a reservoir for
the HIV population. Because of these cells, the virus population does not die out, even if
therapy is very successful and there is (almost) no replication.
Simulation details. Time is counted in generations. Each generation is split in 10 time-
steps. At each time step, each viral particle has a probability of 1/10 to be chosen to reproduce
and die. The expected life-time of a viral particle is therefore 1 generation and this is the same
for wildtype and resistant virus. All particles that are chosen to reproduce at a given time-step
die and are replaced by their offspring (i.e. newly infected cells). The number of offspring is
equal to [number of chosen wildtype particles]∗[Fwt]+[number of chosen resistant particles]∗
[Fres]. If this number is smaller than 20, stochastic effects should be taken into account, so
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instead of using the number directly, we take a random number from the Poisson distribution
with the expected number as the mean. If adding of the new offspring to the population would
lead the population size to be higher than K, we add fewer individuals so that the population
size will be exactly K. The new offspring can be either wildtype or resistant. It is assigned
a type at random, with probability
[number of chosen wildtype particles] ∗ [Fwt]
[number of chosen wildtype particles] ∗ [Fwt] + [number of chosen res particles] ∗ [Fres]
to be wildtype, and resistant otherwise. This is a standard procedure (also used in Hermisson
and Pennings 2005) The choice of 10 time-steps per generation is a compromise between the
speed of simulating discrete generations and the reality of continuous replication.
Mutation occurs only from wildtype to resistant. Back-mutation to wildtype is ignored.
The number of mutations in a generation depends on the (per particle and per generation)
mutation rate, µ, and the number of newly created infected cells, which in turn depends on
fitness and population size.
Analytical calculation of the fixation probability. To calculate the probability that
resistance mutations become established when treatment is started (either for the first time
or after an interruption), there are two possibilities. When the relative cost of resistance in
the absence of drugs, the fitness of the resistant virus with drugs and the viral population size
are all known, we can use the theory from Hermisson and Pennings (2005) to calculate the
probability that resistance mutations from the standing genetic variation become established.
Alternatively, if the number of copies of the resistant virus and the fitness of resistant virus are
known, it is possible to calculate the probability that at least one of these copies will survive,
in which case the population becomes resistant. For the latter, we need the probability
that a single resistant mutant spreads in the population and ultimately goes to fixation, as
opposed to being lost due to genetic drift. In the current model, individuals (viral particles
in infected cells) will “produce” a Poisson distributed number of newly infected cells (we call
these offspring). The mean number of offspring, λ, determines the probability that a lineage
dies out or survives. Usually, it is assumed that the mean number of offspring of a genotype
depends on its fitness relative to the mean fitness of the population. However, when a patient
takes drugs, the population size of the virus will be much lower than the carrying capacity,
so that there is effectively no competition between resistant and wildtype virus. The mean
number of offspring, λ, therefore does not depend on the relative fitness, but simply equals
the absolute fitness of the resistant virus. In 1927, Haldane showed that the relationship
between the mean number of offspring (λ) and the fixation probability is
(6) λ = − log(1− Pfix)
Pfix
= 1 +
Pfix
2
+
P 2fix
3
+
P 3fix
4
+
P 4fix
5
+O(P 5fix)
Traditionally, the fixation probability is calculated using the selection coefficient, sb =
Fres−Fwt
Fwt
, instead of the expected number of offspring, λ. In a population with stable pop-
ulation size and competition between genotypes this is fine because λ = 1 + sb, but in the
current model, this does not hold and sb is irrelevant.
If λ− 1 is small, a simple approximation for the fixation probability is:
(7) Pfix ≈ 2(λ− 1)
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When λ is larger, Haldanes equation needs to be solved numerically using more terms of
the Taylor expansion.
10.2. Data from clinical trials. Starting standard therapy. The probability that resis-
tance mutations from standing genetic variation become established at the start of therapy
was estimated from a data set that was published in Margot (2006), see table 3 for the
raw data. The study reported the number of patients where resistance was detected in the
first, second and third year of treatment, for two treatment groups and for three categories
of resistance mutations. Because in each case only the first resistance mutation in a given
patient was recorded, the data for the three different resistance classes could not be analyzed
separately. A saturated model was fitted using R (R Development Core Team, 2005) after
which non-significant interactions were removed. It was found that the probability that re-
sistance mutations became established did not differ significantly between the two treatment
groups (p=0.26) and also not between year 2 and year 3 (p=0.78). However, there was a
clear difference between year 1 and the other two years (p < 10−5). The average risk per
year in year 2 and 3 was 3.7%, whereas the average risk in year 1 was 9.5%. The difference
between year 1 and the other 2 years was 5.8%, which could be due to the standing genetic
variation before treatment started.
Single dose nevirapine. We searched the web of science (ISI) database for published
studies on single dose nevirapine and resistance. We limited ourselves to studies that reported
the fraction of women that had detectable resistance at 4 to 6 weeks postpartum using
standard sequencing. An overview of the studies can be found in table 4.
Interruption studies. Seven studies were identified that reported on clinical trials in
which patients interrupted treatment multiple times for a fixed length of time (i.e., all pa-
tients in the trial were on the same schedule) and which tested genotypic resistance on plasma
samples of all patients in which treatment failed (and ideally of all patients) before and after
the trial. Characteristics of the seven studies can be found in table 5 (supplementary mate-
rial). The shortest interruption length was two days and the longest 60 days. If possible, we
removed patients which had evidence of resistance before the trial started. In all but one of
the studies, patients were on traditional triple-drug regimens (NNRTI or PI based with two
NRTIs). Only in the Staccato study some patients were on a boosted PI regimen (Anan-
woranich et al, 2003). These patients were taken out of the analysis because resistance seems
to evolve much slower in regimens with boosted PI’s compared to NNRTI and unboosted PI
regimens (Lima, 2008). In two trials, the interruptions had varying lengths (Hoen 2005 and
Palmisano 2007), in which case we used the mean length of the interruptions for the plot
(these points are in grey in the plot, see figure 6).
For each study, the fraction of patients (F ) which did not acquire any resistance mutations
during the trial was calculated. The number of treatment interruptions (T ) which were
relevant for the resistance data was calculated. For example, if genotypic resistance tests were
done on samples that were obtained during treatment interruption 4, it was assumed that any
resistance had occurred due to treatment interruption 1, 2 or 3 so that T = 3. Furthermore
it was assumed that each treatment interruption (TI ) contributed equally to the probability
that resistance mutations became established. The probability (P ) that resistance mutations
became established due to a single interruption was calculated as follows:
(8) F = (1− P )T ⇒ P = 1− F 1/T
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Two of the studies also allowed for an estimation of the risk that resistance mutations
became established during continuous treatment (Reynolds 2009 and 2010, and Danel 2009).
We find a rate of evolution of resistance of 4.3% and 4.8% per year (see table 5). Using
the mean of these two rates, we can estimate the probability that resistance mutations be-
came established during the time on treatment in each of the trials and we corrected the
estimated risk of an interruption by subtracting the probability that resistance mutations
became established during treatment.
10.3. Supplementary tables.
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Table 3. Number of patients with at least one resistance mutation detected by the
end of the first, second and third year of NNRTI-based antiretroviral therapy. Data
from Margot et al (2006).
Year Group Resistant Not Resistant
1 TDF 35 264
2 TDF 8 256
3 TDF 9 247
1 d4T 22 279
2 d4T 10 269
3 d4T 11 258
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Table 4. Overview of clinical trials with single dose nevirapine which reported the
number of patients with nevirapine resistance detected 6 to 8 weeks after treatment.
Reference and name trial Number of
patients
Treatment Treatment code Est. prob of es-
tablishment of
resistance
Remarks
Eshleman 2005, Malawi 65 sdNVP sdNVP 0.69
Eshleman 2005, Uganda 241 sdNVP sdNVP 0.26
Farr 2010, Malawi 65 sdNVP sdNVP 0.34
Hudelson 2010 , Uganda 30 sdNVP sdNVP 0.43
Jackson 2000, Uganda 15 sdNVP sdNVP 0.20
Kassaye 2007, Zimbabwe 32 sdNVP sdNVP 0.35
Lee 2005, Zimbabwe 32 sdNVP sdNVP 0.34
Loubser 2006, South Africa 44 sdNVP sdNVP 0.54 Results only for
K103N mutation
Ly 2007, Cambodia 35 sdNVP sdNVP 0.23
Martinson 2009, South
Africa, HIVNET 012
108 sdNVP sdNVP 0.38
Martinson 2009, South
Africa, HIVNET 012
193 sdNVP sdNVP 0.46
McIntyre 2009, South
Africa
74 sdNVP sdNVP 0.59
Rajesh 2010, India 12 sdNVP sdNVP 0.33
Toni 2005, Ivorycoast 29 sdNVP sdNVP 0.21
Farr 2010, Malawi 120 sdNVP + 7 days
3TC/ZDV
sdNVP/PP 0.017
McIntyre 2009, South
Africa
164 sdNVP + 4 days
3TC/ZDV
sdNVP/PP 0.097
McIntyre 2009, South
Africa
168 sdNVP + 7 days
3TC/ZDV
sdNVP/PP 0.073
Chaix 2007, Ivorycoast,
ANRS/Ditrame Plus
63 ZDV from 36 weeks +
sdNVP
ZDV/sdNVP 0.33
Chalermchokcharoenkit
2009, Thailand
190 ZDV 3rd trimester +
sdNVP
ZDV/sdNVP 0.18
Chi 2009 and 2007, Zambia 166 ZDV 3rd trimester +
sdNVP
ZDV/sdNVP 0.25
Lallemant 2009, Thailand,
PHPT2
222 ZDV 3rd trimester +
sdNVP
ZDV/sdNVP 0.064
Ly 2007, Cambodia 16 ZDV from 28 weeks +
sdNVP
ZDV/sdNVP 0.19
Shapiro 2006, Botswana 155 ZDV from 34 weeks +
sdNVP
ZDV/sdNVP 0.45
Van Zijl 2008, South Africa 76 ZDV from 34 weeks +
sdNVP
ZDV/sdNVP 0.17
Arrive 2010, Cambo-
dia/Ivorycoast/South
Africa, TEmAA ANRS
12109
33 ZDV from enrollment
+ sdNVP + 1 week
TDF/FTC
ZDV/sdNVP/PP 0.0
Dabis 2009, Cambo-
dia/Ivorycoast/South
Africa, TEmAA ANRS
12109
37 ZDV from enrollment
+ sdNVP + 1 week
TDF/FTC
ZDV/sdNVP/PP 0.0
Lallemant 2009, Thailand,
PHPT4
222 ZDV 3rd trim +
sdNVP + 1 month
ZDV/DDI
ZDV/sdNVP/PP 0.0
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Table 5. Overview of clinical trials with structured treatment interruptions which
reported the number of patients with at least one drug resistance mutation detected.
Reference and name
trial
% on
PI
Number
of pa-
tients
Patients
excluded
Patients
with
genotypic
resistance
Fraction
not re-
sistant
at end of
trial
TI’s
rele-
vant for
calcula-
tion
Length
of TI
(days)
Treatment
period
(days)
Est. prob
of evo-
lution of
resistance
per TI
Corrected
prob of
evolu-
tion of
resistance
Interruption arms
Reynolds 2009
and 2010, Uganda
FOTO arm
2% 57 1 (no geno-
type)
4 52/56 72 2 5 0 0
Ananworanich
2003, Staccato
WOWO arm
0% 36 22 (on
boosted
PI) 2 (had
resistance
before
trial)
3 9/12 17 7 7 0.02 0.02
Reynolds 2009
and 2010, Uganda
WOWO arm
6% 32 3 (left the
trial)
9 20/29 18 7 7 0.02 0.02
Yerly 2003 , SSITT
trial
100% 87 4 (lost to
follow-up)
3 (already
resistance
before
trial)
11 69/80 4 14 56 0.04 0.03
Hoen 2005, ANRS
100 Primstop trial
100% 26 4 (re-
sistance
before
trial) 1
(resistance
in first TI)
2 19/21 2 14, 28
(mean
21)
84 0.05 0.04
Palmisano 2007,
ISS PART
25% 136 16 (es-
timated
number
that had
resistance
before)
22 98/120 3 28,
28, 56
(mean
37)
91 0.07 0.06
Danel 2009,
Ivory Coast NCT
00158405
10% 325 10 (no
genotypes)
76 239/315 4 60 91 0.07 0.06
Continuous arms
Reynolds 2009 and
2010, Uganda con-
tinuous arm
2% 51 0 3 48/51 – – 504 – 0.043/year
Danel 2009,
Ivory Coast NCT
00158405
15% 110 3 (no geno-
types)
10 97/107 – – 728 – 0.048/year
